Synthetic ETP Analogues Modulate Toxicity and Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ETP natural products exhibit high toxicity, preventing clinical studies, and lack detailed SAR studies or modification of properties like water solubility, membrane permeability, and metabolic stability, necessitating a synthetic route for medicinal use.
Innovation Solution
Development of synthetic analogues of ETP compounds with varied functional groups for potential cancer treatment, including methods for synthesis and combination with other cancer therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural ETP compounds are used for cancer treatment, then biological activity is achieved, but high toxicity prevents clinical studies
Solution Approach 1:
The patent applies local quality by introducing specific functional groups at particular positions on the ETP core structure. Different substituents (R1, R2, R3 groups) are strategically placed to modulate local properties of the molecule, thereby reducing overall toxicity while preserving the essential biological activity at the target site.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as substituent types, chain lengths, and functional group configurations. These parameter modifications allow optimization of the toxicity profile while maintaining anticancer activity, enabling compounds to pass clinical safety thresholds.
2Quantity of substance
If ETP structures are modified to improve water solubility, then solubility increases, but membrane permeability may be compromised
Solution Approach 1:
The patent introduces polar functional groups (such as hydroxyl, carboxyl, or amine groups) at specific locations on the ETP scaffold to enhance water solubility locally. These polar regions increase aqueous solubility without uniformly affecting the entire molecule's hydrophobic character, thereby preserving membrane permeability properties.
Solution Approach 2:
The patent creates composite molecular structures by combining hydrophilic functional groups with the hydrophobic ETP core. This composite approach allows the molecule to exhibit both water solubility (from the hydrophilic groups) and membrane permeability (from the hydrophobic core), resolving the contradiction between these two properties.
3Reliability
If ETP analogues are synthesized with varied functional groups, then medicinal properties are optimized, but synthesis complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the synthesis into modular stages: first establishing the core ETP structure, then sequentially adding functional groups at specific positions. This segmented approach allows independent optimization of each substituent without requiring complete redesign of the entire synthesis pathway, thereby managing complexity while achieving medicinal property optimization.
Solution Approach 2:
The patent employs universal intermediates and protecting group strategies that can be applied across multiple ETP analogue syntheses. By developing a core set of versatile synthetic building blocks and reaction conditions, the patent reduces the incremental complexity of synthesizing different analogues, allowing systematic exploration of structure-activity relationships.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided herein, inter alia, is the synthesis of ETP derivatives. The uses of the ETP derivatives described herein include treatment of cancer.